Visual confusion for Monocular Double Vision
N/A
Waitlist Available
Led By JaeHyun Jung
Research Sponsored by Massachusetts Eye and Ear Infirmary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
No restrictions of the peripheral visual field: (at least 60 degrees vertically and 40 degrees horizontally)
Able to understand English
Must not have
Timeline
Screening 3 weeks
Treatment Varies
Follow Upapproximately 1-2 sessions to finish total 6 trials, up to 2 hours for each session, any time within the 4month study period
Awards & highlights
No Placebo-Only Group
Study Summary
This trial will help researchers understand how our brain processes information from what we see.
Eligible Conditions
- Binocular Vision Suppression
- Monocular Double Vision
- Binocular Fusion Defect
- Double Vision
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowSelect...
You need to have a wide enough visual field (60 degrees vertically and 40 degrees horizontally) to participate in the study.
Select...
You can speak and understand English.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 1-2 sessions to finish total 6 trials, up to 2 hours for each session, any time within the 4month study period
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 1-2 sessions to finish total 6 trials, up to 2 hours for each session, any time within the 4month study period
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage of Total Viewing Time That Peripheral Target is Perceived
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Visual confusionExperimental Treatment3 Interventions
Participants viewed peripheral targets in three different visual confusion conditions (three interventions): binocular visual confusion (unilateral opaque target), unilateral monocular visual confusion (unilateral see-through target), and bilateral monocular visual confusion (bilateral see-through target). Each intervention was presented twice in a randomized order, resulting in a total of six trials. During each trial, a peripheral target was presented in front of a forward-moving background for one minute. Participants were instructed to hold down the controller button while the target was visible and release it when a third or more of the target disappeared. After each trial, participants could take a brief break before the next trial in a different visual confusion condition was presented in a randomized order.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Unilateral monocular visual confusion (unilateral see-through)
2021
N/A
~20
Bilateral monocular visual confusion (bilateral see-through)
2021
N/A
~20
Binocular visual confusion (unilateral opaque)
2021
N/A
~20
Find a site
Who is running the clinical trial?
National Eye Institute (NEI)NIH
531 Previous Clinical Trials
1,198,081 Total Patients Enrolled
Massachusetts Eye and Ear InfirmaryLead Sponsor
104 Previous Clinical Trials
12,539 Total Patients Enrolled
JaeHyun JungPrincipal Investigator
Schepens Eye Research InstituteFrequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the magnitude of participants in this research endeavor?
"Affirmative, the information hosted on clinicaltrials.gov verifies that this medical trial is still recruiting patients. It was initially brought to light on November 9th 2021 and last updated at the same time; 30 individuals are needed from a single research site."
Answered by AI
Is the experiment currently open to participants?
"Affirmative. Clinicaltrials.gov has information showing that this trial was first posted on November 9th 2021 and is still actively recruiting participants, with a total of 30 patients needed from 1 site."
Answered by AI